60 Degrees Pharmaceuticals (SXTP) News Today → Forget the “Magnificent 7” Tech Companies, Buy This AI Stock Instead (From Banyan Hill Publishing) (Ad) Free SXTP Stock Alerts $0.23 +0.01 (+4.55%) (As of 09:30 AM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 8, 2024 | finance.yahoo.com60 Degrees Pharmaceuticals Outlines Upcoming Clinical Trial of Tafenoquine in Babesiosis in Letter to Journal of Infectious DiseasesMay 8, 2024 | globenewswire.com60 Degrees Pharmaceuticals Outlines Upcoming Clinical Trial of Tafenoquine in Babesiosis in Letter to Journal of Infectious DiseasesMay 2, 2024 | globenewswire.com60 Degrees Pharmaceuticals Receives FDA Comments on Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes RequiredApril 18, 2024 | msn.com60 Degrees Pharmaceuticals (SXTP) Price Target Increased by 8.33% to 1.33April 3, 2024 | finance.yahoo.com60 Degrees Pharmaceuticals to Sponsor Pilot Study of Tafenoquine for Treatment of Canine BabesiosisApril 3, 2024 | globenewswire.com60 Degrees Pharmaceuticals to Sponsor Pilot Study of Tafenoquine for Treatment of Canine BabesiosisMarch 14, 2024 | globenewswire.com60 Degrees Pharmaceuticals Announces Communication from the FDA of Intention to Respond to Tafenoquine-Babesiosis Trial Protocol Submission in April, 2024February 20, 2024 | finance.yahoo.com60 Degrees Pharmaceuticals to Sponsor Pre-Clinical Studies of Tafenoquine Use in Candida spp, Including Candida aurisFebruary 20, 2024 | globenewswire.com60 Degrees Pharmaceuticals to Sponsor Pre-Clinical Studies of Tafenoquine Use in Candida spp, Including Candida aurisFebruary 8, 2024 | finance.yahoo.com60 Degrees Pharmaceuticals Appoints Kristen Landon as Chief Commercial OfficerJanuary 31, 2024 | finance.yahoo.com60 Degrees Pharmaceuticals Announces Closing of $2.4 Million Public OfferingJanuary 31, 2024 | finance.yahoo.comWallachBeth Capital Announce Closing of 60 Degrees Pharmaceuticals $2.4 Million Public OfferingJanuary 30, 2024 | marketwatch.com60 Degrees Shares Plumb New Lows After Public OfferingJanuary 30, 2024 | morningstar.com60 Degrees Pharmaceuticals IncJanuary 30, 2024 | finance.yahoo.comWallachBeth Capital Announces Pricing of 60 Degrees Pharmaceuticals $2.4 Million Public OfferingJanuary 30, 2024 | markets.businessinsider.comWhy Is 60 Degrees (SXTP) Stock Down 33% Today?January 30, 2024 | finance.yahoo.com60 Degrees Pharmaceuticals Announces Pricing of $2.4 Million Public OfferingJanuary 22, 2024 | msn.com60 Degrees Pharmaceuticals files to sell 4.79M unitsJanuary 22, 2024 | msn.comWhy Is 60 Degrees Pharmaceuticals Stock Trading Higher Today?January 22, 2024 | marketwatch.com60 Degrees Pharma Shares Rise 18% After Type C Meeting With FDAJanuary 22, 2024 | finance.yahoo.com60 Degrees Pharma Plans Pivotal Babesiosis Study with Tafenoquine Following Jan 17 FDA MeetingJanuary 16, 2024 | finance.yahoo.com60 Degrees Pharma Regains Compliance with Nasdaq Listing RequirementsDecember 28, 2023 | marketwatch.com60 Degrees Pharmaceuticals Shares Surge 28% on Approved Study of Tafenoquine as Potential Bbesiosis TreatmentDecember 26, 2023 | msn.comWhy Is Infection Treatment Focused-60 Degrees Pharmaceuticals Stock Soaring Today?December 26, 2023 | finance.yahoo.com60 Degrees Pharma Announces IRB Approval of Phase IIA Study to Evaluate Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease; Type C Meeting Re-Scheduled by FDA to January 17, 2024November 15, 2023 | msn.com60 Degrees to meet with FDA over developing Arakoda for babesiosisNovember 15, 2023 | sg.finance.yahoo.com60 Degrees Pharmaceuticals, Inc. (SXTP)November 15, 2023 | finance.yahoo.com60 Degrees Pharma Announces Type C Meeting with FDA to Discuss Development of Tafenoquine for Babesiosis, an Emerging Tick-Borne DiseaseOctober 20, 2023 | markets.businessinsider.comHold Rating Recommended for 60 Degrees Pharmaceuticals due to Uncertain Profitability and Strategic ShiftOctober 19, 2023 | finance.yahoo.com60 Degrees Pharma to Present Review of Safety, Efficacy Data of 8-Aminoquinolines for Malaria and Babesiosis Treatment at ILADS Annual Scientific Meeting in BostonOctober 12, 2023 | finance.yahoo.com60 Degrees Pharmaceuticals Suspends Phase IIB Study of Tafenoquine for COVID-19, Pivots to Refocus on Commercialization of Treatments for Malaria and Tick-Borne DiseasesOctober 12, 2023 | marketbeat.comTrading was temporarily halted for "SXTP" at 04:10 PM with a stated reason of "News pending."September 20, 2023 | barrons.com60 Degrees Pharmaceuticals Inc.September 20, 2023 | msn.comWhy Is Infectious Disease Focused 60 Degrees Pharmaceuticals Stock Trading Lower Today?September 18, 2023 | reuters.com60 Degrees Pharma withdraws mid-stage study application for COVID drugSeptember 18, 2023 | finance.yahoo.com60 Degrees Pharma Withdraws COVID Phase IIB IND, Will Resubmit Pending Assessment of Ability to Meet FDA RequirementsSeptember 6, 2023 | finance.yahoo.com60 Degrees Pharmaceuticals to Participate in H.C. Wainwright 25th Annual Global Investment ConferenceSeptember 1, 2023 | finance.yahoo.comGenetic Technologies Limited and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Money Report® on Bloomberg TVSeptember 1, 2023 | finance.yahoo.comGenetic Technologies Limited and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Money Report(R) on Bloomberg TVAugust 30, 2023 | finance.yahoo.com60 Degrees Pharmaceuticals Study Results Published by New Microbes and New Infections Demonstrate Tafenoquine Exhibits Broad Spectrum Antifungal ActivityAugust 22, 2023 | finance.yahoo.com60 Degrees Pharmaceuticals Receives Additional U.S. Patent Covering Tafenoquine for Prevention of Plasmodium Falciparum MalariaAugust 15, 2023 | uk.investing.com60 Degrees Pharmaceuticals Inc (SXTP)August 15, 2023 | finance.yahoo.com60 Degrees Pharmaceuticals Registers ACLR8-LR, a Phase IIB Study of Tafenoquine for Treatment of COVID-19, on ClinicalTrials.govAugust 14, 2023 | finance.yahoo.com60 Degrees Pharmaceuticals Awarded Canadian Patent Covering Tafenoquine for Prevention of Malaria in Malaria-Naive SubjectsJuly 13, 2023 | investorplace.comWhy Is 60 Degrees Pharmaceuticals (SXTP) Stock Up 17% Today?July 13, 2023 | marketbeat.comTrading was temporarily halted for "SXTP" at 09:07 AM with a stated reason of "LULD pause."July 13, 2023 | marketbeat.comTrading was temporarily halted for "SXTP" at 09:07 AM with a stated reason of "LULD pause." Get 60 Degrees Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SXTP and its competitors with MarketBeat's FREE daily newsletter. Email Address is this a buy and hold stock? (Ad)“Simply Wall Street” LOVES this stock as a Buy and Hold. It’s surging now! …. Click here to learn more SXTP Media Mentions By Week SXTP Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SXTP News Sentiment▼1.230.56▲Average Medical News Sentiment SXTP News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SXTP Articles This Week▼21▲SXTP Articles Average Week Get 60 Degrees Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SXTP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ALLR News Today SNOA News Today CWBR News Today SLRX News Today DRMA News Today CYTO News Today ATXI News Today CNSP News Today VRPX News Today GLMD News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SXTP) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Monetary GoldBiden to Drop BOMBSHELL June 13th?Paradigm PressForget the “Magnificent 7” Tech Companies, Buy This AI Stock InsteadBanyan Hill Publishingis this a buy and hold stock?Tips4TradersWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks NewsThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeTrue Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 60 Degrees Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
